JCVI has now issued updated advice in relation to COVID-19 vaccination of children and young people. The full JCVI statement can be found here...
Read MoreCOVID-19 certificates can be used to demonstrate an individual’s vaccine status and may be required as a condition of entry to specified venues. While the majority of individuals are able to safely receive COVID-19 vaccination,...
Read MoreThe four Chief Medical Officers of the UK and lead DCMOs for vaccines have considered whether, in the light of the very considerable need to speed up vaccination and boosting in the light of the omicron variant the 15 minute...
Read MoreRead the full statement here The Chief Medical Officers (CMOs) of the UK and lead Deputy Chief Medical Officers (DCMOs) for vaccines have considered whether, in the light of the very considerable need to speed up vaccination and...
Read MoreJCVI advises the following immediate measures within the COVID-19 vaccine programmes: Booster vaccination eligibility should be expanded to include all adults aged 18 years to 39 years. Booster vaccination should now be...
Read MoreHSS(MD) 75/2021 PATIENTS REQUIRING ASTRAZENECA VACCINE AS A BOOSTER The JCVI advises a preference for an mRNA vaccine as the booster dose, irrespective of which vaccine was given in the primary schedule. There is good evidence...
Read MoreThe Joint Committee on Vaccination and Immunisation (JCVI) has previously advised: 2 doses of the Pfizer-BioNTech COVID-19 vaccine in children and young people aged 16 to 17 years with an underlying health condition that places...
Read MoreBooster info added to Greenbook Booster information on Covid vaccination added to the Greenbook Page 21 sets out the criteria for a third primary dose of COVID-19 vaccine....
Read MoreTransporting Pfizer Covid 19 vaccine This SOP describes the process for transporting Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) from PCN Designated Sites to end user location in the same PCN.This SOP is applicable to both...
Read MoreJoint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination JCVI advises that a third primary dose be offered to individuals aged 12 years and over with severe immunosuppression in proximity...
Read More